Overview

The diagnosis and treatment of gastrointestinal and liver diseases have rapidly evolved, significantly altering patient care approaches. New pharmacological developments have revolutionized the management of Crohn's disease, ulcerative colitis, and viral hepatitis. Additionally, advancements in endoscopic and imaging techniques have reshaped our diagnostic and therapeutic strategies for pancreaticobiliary diseases, motility disorders, and early luminal neoplasia. These changes have created a knowledge gap in current patient treatment methodologies. This conference aims to update community standards of practice, covering cancer screening guidelines, obesity management, and various topics in luminal, pancreatic, and liver diseases. It emphasizes the latest advancements in Gastroenterology and Hepatology, which hold the potential to enhance patient care.

Learning Objectives

By the end of the course, participants will be able to:

• Identify advances in third-space endoscopy and complicated biliary cases.
• Explain the role of supportive techniques in the evaluation of esophageal disorders and how best to evaluate belching, bloating, distention, and other common GI symptoms.
• Review updates in the medical management of IBD and the management of dysplasia.
• Outline the newest screening and surveillance approaches for colorectal and pancreatic cancer.
• Describe the evaluation process for both living liver donors and recipients, encompassing medical, surgical, and patient perspectives, to ensure optimal outcomes and minimize risks associated with living donor liver transplants.
• Recognize the pathophysiology and clinical implications of acute kidney injury in cirrhosis, including its impact on patient prognosis and management strategies, to improve early detection and treatment approaches in clinical practice.
• Review the latest advancements in treatments for hepatocellular carcinoma (HCC), including surgical, locoregional, and systemic therapies.
• Describe methods to optimize the care of the ambulatory patient with cirrhosis and prevent decompensation.
• Discover insights into recent advances in managing metabolic dysfunction associated with steatohepatitis (MASH), including pharmacological and lifestyle interventions, to address the growing burden of MASH-related liver disease and improve patient outcomes.
• Examine the latest developments in hepatitis B treatment, including antiviral therapies.

Accreditation

The Keck School of Medicine of the University of Southern California is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Keck School of Medicine of the University of Southern California designates this Live Activity activity for a maximum of 9.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.